ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-02
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of 15-week treatment with ALXN2420 versus placebo for decreasing insulin-like growth factor IGF-1 levels, when administered in combination with somatostatin analog (SSA) therapy to adult participants with acromegaly.